Maintenance of this transcription signature in NPM1 cells depends directly on the menin–KMT2A interaction, supporting the role of menin inhibitors in the treatment of NPM1-mutated AML [32,38]. The gene discussed is MEN1; the disease is acute myeloid leukemia.